ClinicalTrials.gg
CompletedNCT03665038Updated Sep 15, 2025Results posted

A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)

A Phase 3 interventional study of Brexanolone in Post Partum Depression, sponsored by Supernus Pharmaceuticals, Inc.. Completed at 17 sites in United States. Open to female participants aged 15 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-09-15.

Sponsored by Supernus Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
15 Years to 17 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 220 studies in Depression, Postpartum with a site in United States — 38 open to participants now, 49 under way, 3 of them phase 3. Depression, Postpartum · United States.

Enrollment
159th of 198
28 · median 86
Started
2018
with 13 others
Phase 3
12 of 220
1 open now
Registered
99th of 220
by date
Lead sponsor
6 of 220
Supernus Pharmaceuticals, Inc.

Among the 220 studies in Depression, Postpartum with a site in United States, this one is the 159th largest by enrollment of the 198 interventional ones that give a count, is one of 14 that started in 2018, is one of 12 in phase 3, and was the 99th registered.

Depression, Postpartum

569 studies on the registry are indexed under Depression, Postpartum; 134 are open to participants now.

Browse Depression, Postpartum studies →

Open to participants now

38 of the 220 studies in Depression, Postpartum with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 87 Depression, Postpartum studies recruiting now, 54 (62%) set no upper age limit and 30 (34%) stop at 75 or younger; 13 take children under 18; 40 take healthy volunteers.

This study: 15 Years to 17 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 220 studies in Depression, Postpartum with a site in United States, or all of them as a file.
02

Study summary

This is a multi-center study evaluating the safety, tolerability, and pharmacokinetics of brexanolone in the treatment of adolescent female participants with postpartum depression (PPD).

03

Conditions studied

  • Post Partum Depression
04

Who can participate

Ages eligible
15 Years to 17 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Participant has had a major depressive episode that began no earlier than the third trimester and no later than the first 4 weeks following delivery, as diagnosed by Structured Clinical Interview for (DSM-5) Axis I Disorders (SCID-5).
  2. Participant is ≤6 months postpartum at screening.

Key Exclusion Criteria:

  1. Active psychosis
  2. Attempted suicide during current episode of PPD
  3. Medical history of bipolar disorder, schizophrenia, and/or schizoaffective disorder.

Note: Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Brexanolone

    Participants will receive a 60-hour single continuous IV infusion of brexanolone, at 30 mcg/kg/hour (0 to 4 hours), at 60 mcg/kg/hour (4 to 24 hours), at 90 mcg/kg/hour (24 to 52 hours), followed by a taper to 60 mcg/kg/hour (52 to 56 hours), and 30 mcg/kg/hour (56 to 60 hours) during the study.

    Drug: Brexanolone

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A TEAE is defined as an AE with onset on or after the start of study drug infusion, or any worsening of a pre-existing medical condition/AE with onset on or after the start of study drug infusion.

    Time frame: From first dose of study drug up to end of follow-up period (up to Day 30)

Secondary outcomes

  1. Area Under the Concentration-Time Curve (AUC) From Time Zero to 60 Hours (AUC0-60)

    Time frame: Day 1: From 0 hour (pre-infusion) and at 4, 8, 12, 24, 30, 36, 48 hours during the infusion; at 60 hours (end of infusion)

  2. AUC From Time Zero to Infinity (AUCinf)

    Time frame: Day 1: From 0 hour (pre-infusion) and at 4, 8, 12, 24, 30, 36, 48 hours during the infusion; at 60 hours (end of infusion)

  3. Maximum (Peak) Plasma Concentration (Cmax)

    Time frame: Day 1: From 0 hour (pre-infusion) and at 4, 8, 12, 24, 30, 36, 48 hours during the infusion; at 60 hours (end of infusion)

  4. Time at Maximum (Peak) Plasma Concentration (Tmax)

    Time frame: Day 1: From 0 hour (pre-infusion) and at 4, 8, 12, 24, 30, 36, 48 hours during the infusion; at 60 hours (end of infusion)

  5. Steady-State Drug Concentration in the Plasma During Constant-Rate Infusion (Css)

    Given that brexanolone is infused to steady-state plasma concentrations, the model-predicted steady-state drug concentration in the plasma during constant-rate infusion value also represents the predicted maximum plasma concentration at the highest infused dose (90 ug/kg/h).

    Time frame: Day 1: From 0 hour (pre-infusion) and at 4, 8, 12, 24, 30, 36, 48 hours during the infusion; at 60 hours (end of infusion)

  6. Average Drug Concentration in Plasma at Steady State During a Dosing Interval (Cavg)

    Cavg was evaluated as the time-weighted average plasma concentrations of brexanolone over the interval.

    Time frame: Day 1: From 0 hour (pre-infusion) and at 4, 8, 12, 24, 30, 36, 48 hours during the infusion; at 60 hours (end of infusion)

  7. Half-Life of First Elimination Phase of Brexanolone (Thalf)

    Half-life is the time required for half of the drug to be eliminated from the serum.

    Time frame: Day 1: From 0 hour (pre-infusion) and at 4, 8, 12, 24, 30, 36, 48 hours during the infusion; at 60 hours (end of infusion)

  8. Clearance of Brexanolone (CL/F)

    Clearance is defined as the volume of plasma from which a substance is completely removed per unit time.

    Time frame: Day 1: From 0 hour (pre-infusion) and at 4, 8, 12, 24, 30, 36, 48 hours during the infusion; at 60 hours (end of infusion)

  9. Steady-State of Volume of Distribution (Vss)

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.

    Time frame: Day 1: From 0 hour (pre-infusion) and at 4, 8, 12, 24, 30, 36, 48 hours during the infusion; at 60 hours (end of infusion)

07

Results

Posted Aug 11, 2022

Participant flow

Participants took part in the study at 8 investigating sites in the United States, from 07 September 2018 to 08 January 2021.

Participant flow — Overall Study
MilestoneDouble-Blind Phase: PlaceboDouble-Blind Phase: BrexanoloneOpen-Label Phase: Brexanolone
Started8812
Completed8811
Not completed001
Withdrew: Lost to follow-up001

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A TEAE is defined as an AE with onset on or after the start of study drug infusion, or any worsening of a pre-existing medical condition/AE with onset on or after the start of study drug infusion.

Time frame:
From first dose of study drug up to end of follow-up period (up to Day 30)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsDouble-Blind Phase: PlaceboDouble-Blind Phase: BrexanoloneOpen-Label Phase: Brexanolone
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)435
SecondaryArea Under the Concentration-Time Curve (AUC) From Time Zero to 60 Hours (AUC0-60)
Time frame:
Day 1: From 0 hour (pre-infusion) and at 4, 8, 12, 24, 30, 36, 48 hours during the infusion; at 60 hours (end of infusion)
Reported as:
Mean · hours*nanograms per milliliter(hr*ng/mL)
Area Under the Concentration-Time Curve (AUC) From Time Zero to 60 Hours (AUC0-60)
hours*nanograms per milliliter(hr*ng/mL)Double-Blind Phase: BrexanoloneOpen-Label Phase: Brexanolone
Area Under the Concentration-Time Curve (AUC) From Time Zero to 60 Hours (AUC0-60)3694.9 ± 397.903516.0 ± 562.85
SecondaryAUC From Time Zero to Infinity (AUCinf)
Time frame:
Day 1: From 0 hour (pre-infusion) and at 4, 8, 12, 24, 30, 36, 48 hours during the infusion; at 60 hours (end of infusion)
Reported as:
Mean · hr*ng/mL
AUC From Time Zero to Infinity (AUCinf)
hr*ng/mLDouble-Blind Phase: BrexanoloneOpen-Label Phase: Brexanolone
AUC From Time Zero to Infinity (AUCinf)4125.9 ± 481.843982.2 ± 709.70
SecondaryMaximum (Peak) Plasma Concentration (Cmax)
Time frame:
Day 1: From 0 hour (pre-infusion) and at 4, 8, 12, 24, 30, 36, 48 hours during the infusion; at 60 hours (end of infusion)
Reported as:
Mean · nanograms per milliliter (ng/mL)
Maximum (Peak) Plasma Concentration (Cmax)
nanograms per milliliter (ng/mL)Double-Blind Phase: BrexanoloneOpen-Label Phase: Brexanolone
Maximum (Peak) Plasma Concentration (Cmax)85.31 ± 9.57181.66 ± 13.528
SecondaryTime at Maximum (Peak) Plasma Concentration (Tmax)
Time frame:
Day 1: From 0 hour (pre-infusion) and at 4, 8, 12, 24, 30, 36, 48 hours during the infusion; at 60 hours (end of infusion)
Reported as:
Median · hour (hr)
Time at Maximum (Peak) Plasma Concentration (Tmax)
hour (hr)Double-Blind Phase: BrexanoloneOpen-Label Phase: Brexanolone
Time at Maximum (Peak) Plasma Concentration (Tmax)52.20 (52.0 to 52.4)52.30 (52.1 to 54.9)
SecondarySteady-State Drug Concentration in the Plasma During Constant-Rate Infusion (Css)

Given that brexanolone is infused to steady-state plasma concentrations, the model-predicted steady-state drug concentration in the plasma during constant-rate infusion value also represents the predicted maximum plasma concentration at the highest infused dose (90 ug/kg/h).

Time frame:
Day 1: From 0 hour (pre-infusion) and at 4, 8, 12, 24, 30, 36, 48 hours during the infusion; at 60 hours (end of infusion)
Reported as:
Number · ng/mL
Steady-State Drug Concentration in the Plasma During Constant-Rate Infusion (Css)
ng/mLDouble-Blind Phase: BrexanoloneOpen-Label Phase: Brexanolone
Steady-State Drug Concentration in the Plasma During Constant-Rate Infusion (Css)79.479.4
SecondaryAverage Drug Concentration in Plasma at Steady State During a Dosing Interval (Cavg)

Cavg was evaluated as the time-weighted average plasma concentrations of brexanolone over the interval.

Time frame:
Day 1: From 0 hour (pre-infusion) and at 4, 8, 12, 24, 30, 36, 48 hours during the infusion; at 60 hours (end of infusion)
Reported as:
Mean · ng/mL
Average Drug Concentration in Plasma at Steady State During a Dosing Interval (Cavg)
ng/mLDouble-Blind Phase: BrexanoloneOpen-Label Phase: Brexanolone
Average Drug Concentration in Plasma at Steady State During a Dosing Interval (Cavg)61.59 ± 6.63958.60 ± 9.386
SecondaryHalf-Life of First Elimination Phase of Brexanolone (Thalf)

Half-life is the time required for half of the drug to be eliminated from the serum.

Time frame:
Day 1: From 0 hour (pre-infusion) and at 4, 8, 12, 24, 30, 36, 48 hours during the infusion; at 60 hours (end of infusion)
Reported as:
Mean · hour
Half-Life of First Elimination Phase of Brexanolone (Thalf)
hourDouble-Blind Phase: BrexanoloneOpen-Label Phase: Brexanolone
Half-Life of First Elimination Phase of Brexanolone (Thalf)12.24 ± 0.46612.55 ± 1.096
SecondaryClearance of Brexanolone (CL/F)

Clearance is defined as the volume of plasma from which a substance is completely removed per unit time.

Time frame:
Day 1: From 0 hour (pre-infusion) and at 4, 8, 12, 24, 30, 36, 48 hours during the infusion; at 60 hours (end of infusion)
Reported as:
Mean · liters per hour (L/hr)
Clearance of Brexanolone (CL/F)
liters per hour (L/hr)Double-Blind Phase: BrexanoloneOpen-Label Phase: Brexanolone
Clearance of Brexanolone (CL/F)66.86 ± 13.85877.88 ± 18.026
SecondarySteady-State of Volume of Distribution (Vss)

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.

Time frame:
Day 1: From 0 hour (pre-infusion) and at 4, 8, 12, 24, 30, 36, 48 hours during the infusion; at 60 hours (end of infusion)
Reported as:
Mean · liters (L)
Steady-State of Volume of Distribution (Vss)
liters (L)Double-Blind Phase: BrexanoloneOpen-Label Phase: Brexanolone
Steady-State of Volume of Distribution (Vss)448.1 ± 70.34588.5 ± 187.53

Adverse events

Collected over From first dose of study drug up to end of follow-up period (up to Day 30). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-Blind Phase: Placebo0/8 (0%)0/8 (0%)4/8 (50%)
Double-Blind Phase: Brexanolone0/8 (0%)0/8 (0%)3/8 (37.5%)
Open-Label Phase: Brexanolone0/12 (0%)1/12 (8.3%)4/12 (33.3%)
Most frequent serious events
Most frequent serious events
EventDouble-Blind Phase: PlaceboDouble-Blind Phase: BrexanoloneOpen-Label Phase: Brexanolone
DizzinessNervous system disorders0/80/81/12
Loss of consciousnessNervous system disorders0/80/81/12
Most frequent other events
Showing 10 of 12
Most frequent other events
EventDouble-Blind Phase: PlaceboDouble-Blind Phase: BrexanoloneOpen-Label Phase: Brexanolone
Infusion site painGeneral disorders0/82/81/12
DizzinessNervous system disorders0/80/82/12
SedationNervous system disorders0/81/81/12
Infusion site extravasationGeneral disorders1/80/80/12
Infusion site inflammationGeneral disorders1/80/80/12
Infusion site swellingGeneral disorders1/80/80/12
NauseaGastrointestinal disorders1/81/81/12
Localized infectionInfections and infestations1/80/80/12
Upper respiratory tract infectionInfections and infestations0/81/80/12
Weight decreasedInvestigations1/80/80/12

Baseline characteristics

The safety set included all participants administered study drug.

Age, Continuous
Age, Continuous(years)Double-Blind Phase: PlaceboDouble-Blind Phase: BrexanoloneOpen-Label Phase: BrexanoloneTotal
Mean16.6 ± 0.5216.4 ± 0.5216.3 ± 0.7816.4 ± 0.63
Sex: Female, Male
Sex: Female, Male(Participants)Double-Blind Phase: PlaceboDouble-Blind Phase: BrexanoloneOpen-Label Phase: BrexanoloneTotal
Female881228
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Double-Blind Phase: PlaceboDouble-Blind Phase: BrexanoloneOpen-Label Phase: BrexanoloneTotal
Hispanic or Latino0202
Not Hispanic or Latino861226
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Double-Blind Phase: PlaceboDouble-Blind Phase: BrexanoloneOpen-Label Phase: BrexanoloneTotal
American Indian or Alaska Native0011
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American661022
White2215
More than one race0000
Unknown or Not Reported0000
08

Study locations

17 sites
  • Sage Investigational Site
    Tempe, Arizona 85226, United States
  • Sage Investigational Site
    North Little Rock, Arkansas 72758, United States
  • Sage Investigational Site
    Miramar, Florida 33029, United States
  • Sage Investigational Site
    Orlando, Florida 32807, United States
  • Sage Investigational Site
    Pensacola, Florida 32502, United States
  • Sage Investigational Site
    Pinellas Park, Florida 33782, United States
  • Sage Investigational Site
    Pompano Beach, Florida 33060, United States
  • Sage Investigational Site
    Atlanta, Georgia 30331, United States
  • Sage Investigational Site
    Decatur, Georgia 30030, United States
  • Sage Investigational Site
    Edgewood, Kentucky 41017, United States
  • Sage Investigational Site
    Owensboro, Kentucky 42303, United States
  • Sage Investigational Site
    Flowood, Mississippi 39232, United States
  • Sage Investigational Site
    Jackson, Mississippi 39216, United States
  • Sage Investigational Site
    Chapel Hill, North Carolina 27599, United States
  • Sage Investigational Site
    Middleburg Heights, Ohio 44130, United States
  • Sage Investigational Site
    Houston, Texas 77058, United States
  • Sage Investigational Site
    League City, Texas 77573, United States
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Data sharing will be consistent with the results submission policy of ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2018 to primary completion in Jan 2021, 28 months.

Results were first posted in Aug 2022, 1 year 7 months after primary completion. A results delay was requested in Jan 2022.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2018
First posted
Sep 11, 2018
StartActual
Sep 7, 2018
Primary completionActual
Jan 8, 2021
CompletionActual
Jan 8, 2021
Results delay requested
Jan 7, 2022
Results first posted
Aug 11, 2022
Last update
Sep 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03665038
Responsible party
Sponsor
First posted
Sep 11, 2018
Start date
Sep 7, 2018
Primary completion
Jan 8, 2021
Completion
Jan 8, 2021
Results posted
Aug 11, 2022
Last update
Sep 15, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexanolone

Start the discussion